Biological evaluation of cryptophycin 52 fragment A analogues: Effect of the multidrug resistance ATP binding cassette transporters on antitumor activity

Molecular Cancer Therapeutics

Volumn 3, Issue 9, 2004, Pages 1061-1067

  Al Awar, Rima S ^a   Corbett, Thomas H ^b   Ray, James E ^a   Polin, Lisa ^b   Kennedy, Joseph H ^a   Wagner, Margaret M ^a   Williams, Daniel C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMIDE; AMINO ACID; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID; CHLOROHYDRIN DERIVATIVE; CRYPTOPHYCIN 1; CRYPTOPHYCIN 52; CRYPTOPHYCIN 55; CRYPTOPHYCIN DERIVATIVE; DEPSIPEPTIDE; DOXORUBICIN; EPOXIDE; FUNCTIONAL GROUP; GLYCOPROTEIN P; HYDROXYL GROUP; PACLITAXEL; PROTEIN SUBUNIT; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS ADENOMA; PRIORITY JOURNAL; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUMOR MODEL; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DEPSIPEPTIDES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LACTAMS; LACTONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4644364746     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Trimurtulu G, Ohtani I, Patterson GML, et al. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV 224. J Am Chem Soc 1994;116:4729-37.
2. Golakoti T, Ogino J, Heltzel CE, et al. Structure determination, conformational analysis, chemical stability studies, and antitumor evaluation of the cryptophycins. Isolation of 18 new analogs from Nostoc sp. strain GSV 224. J Am Chem Soc 1995;117:12030-49.
3. Moore RE. Cyclic peptides and depsipeptides from cyanobacteria: a review. J Ind Microbiol 1996;16:134-43.
4. Subbaraju GV, Golakoti T, Patterson GML, Moore RE. Three new cryptophycins from Nostoc sp. GSV 224. J Nat Prod 1997;60:302-5.
5. Panda D, Himes RH, Moore RE, Wilson L, Jordan MA. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1. Biochemistry 1997;36:12948-53.
6. Panda D, DeLuca K, Williams D, Jordan MA, Wilson L. Antiproliferative mechanism of action of cryptophycin 52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc Natl Acad Sci 1998;95:9313-8.
7. Panda D, Ananthnarayan V, Larson G, Shih C, Jordan MA, Wilson L. Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochemistry 2000;39:14121-7.
8. Barbier P, Gregoire C, Devred F, Sarrazin M, Peyrot V. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug. Biochemistry 2001; 40:13510-9.
9. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Cancer Agents 2002; 2:1-17.
10. Wagner MM, Paul DC, Shih C, Jordan MA, Wilson L, Williams D. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol 1999;43:115-25.
11. Barrow RA, Hemscheidt T, Liang J, Paik S, Moore RE, Tius MA. Total synthesis of cryptophycins. Revision of the structures of cryptophycins A and C. J Am Chem Soc 1995;117:2479-90.
12. Gardinier KM, Leahy JW. Enantiospecific total synthesis of the potent antitumor macrolides cryptophycins 1 and 8. J Org Chem 1997;62: 7098-9.
13. Ali SM, Georg GI. Formal syntheses of cryptophycin A and arenastatin A. Tetrahedron Lett 1997;38:1703-6.
14. Dhokte UP, Khau VV, Hutchison DR, Martinelli MJ. A novel approach for total synthesis of cryptophycins via asymmetric crotylboration protocol. Tetrahedron Lett 1998;39:8771-4.
15. Varie D, Brennan J, Briggs B, et al. Bioreduction of (R)-carvone and regioselective Baeyer-Villiger oxidations: application to the asymmetric synthesis of cryptophycin fragment A. Tetrahedron Lett 1998;39:8405-8.
16. White JD, Hong J, Robarge LA. Total synthesis of cryptophycins-1, -3, -4, -24 (arenastatin A), and -29, cytotoxic depsipeptides from cyanobacteria of the Nostocaceae. J Org Chem 1999;64:6206-16.
17. Liang J, Hoard DW, Khau VV, et al. Synthesis of unit A of cryptophycin via a [2,3]-Wittig rearrangement. J Org Chem 1999;64:1459-63.
18. Ghosh AK, Bischoff A. A Convergent synthesis of (+)-cryptophycin B, a potent antitumor macrolide from Nostoc sp. cyanobacteria. Org Lett 2000;2:1575-6.
19. Liang J, Moher ED, Moore RE, Hoard DW. Synthesis of cryptophycin 52 using the Sharpless asymmetric dihydroxylation: diol to epoxide transformation optimized for a base-sensitive substrate. J Org Chem 2000;65: 3143-7.
20. Eggen MJ, Nair SK, Georg GI. Rapid entry into the cryptophycin core via an acyl-β-lactam macrolactonization: total synthesis of cryptophycin-24. Org Lett 2001;3:1813-5.
21. Smith AB III, Cho YS, Zawacki LE, Hirschmann R, Pettit GR. First generation design, synthesis, and evaluation of azepine-based cryptophycin analogues. Org Lett 2001;3:4063-6.
22. Eggen MJ, Georg GI. The cryptophycins: their synthesis and anti-cancer activity. Med Res Rev 2002;22:85-101.
23. Tius MA. Synthesis of the cryptophycins. Tetrahedron 2002;58: 4343-67.
24. De Muys J, Rej R, Nguyen D, Go B, Fortin S, Lavallee J. Synthesis and in vitro cytotoxicity of cryptophycins and related analogs. Bioorg Med Chem Lett 1996;6:1111-6.
25. Norman BH, Hemscheidt T, Schultz RM, Andis SL. Total synthesis of cryptophycin analogues. Isosteric replacement of the C-D ester. J Org Chem 1998;63:5288-94.
26. Patel VF, Andis SL, Kennedy JH, Ray JE, Schultz RM. Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment "B" analogues. J Med Chem 1999;42:2588-603.
27. Shih C, Gossett LS, Gruber JM, et al. Synthesis and biological evaluation of novel cryptophycin analogs with modification in the β-alanine region. Bioorg Med Chem Lett 1999;9:69-74.
28. Varie DL, Shih C, Hay DA, et al. Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region). Bioorg Med Chem Lett 1999;9:369-74.
29. Shih C, Al-awar RS, Fray AH, et al. Synthesis and structure-activity relationship studies of cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. ACS Symp Ser 2001;796:171-89.
30. Corbett TH, Valeriote FA, Demchik L, et al. Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol 1996;1:95-108.
31. Georg GI, Ali SM, Stella VJ, Waugh WN, Himes RH. Halohydrin analogues of cryptophycin 1: synthesis and biological activity. Bioorg Med Chem Lett 1998;8:1959-62.
32. Al-awar RS, Ray J, Schultz R, et al. The synthesis and evaluation of novel cryptophycin analogs. Proc AACR 1998;39:425.
33. Al-awar RS, Ray JE, Schultz RM, et al. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment A epoxides and chlorohydrins. J Med Chem 2003;46: 2985-3007.
34. Corbett TH, Valeriote FA, LoRusso P, et al. Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharm 1995;33:102-22.
35. Corbett TH, Valeriote FA, Demchik L, et al. Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 1997;15:207-18.
36. McGrath T, Center MS. Adriamycin resistance in HL-60 cells in the absence of detectable P-glycoprotein. Biochem Biophys Res Commun 1987;145:1171-6.
37. Marsh W, Sicheri D, Center MS. Isolation and characterization of Adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res 1986;46:4053-7.
38. Krishnamachary N, Ma L, Zheng L, Safa AR, Center ML. Analysis of MRP gene expression and function in HL-60 cells isolated for resistance to Adriamycin. Oncol Res 1994;6:119-27.
39. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996;192:768-80.
40. Ramachandran C, Melnick SJ. Multidrug resistance in human tumors-molecular diagnosis and clinical significance. Mol Diagn 1999;4:81-94.